Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 10 | 2025Sernova and Eledon Partner for T1DM; Lilly’s Zepbound KwikPen Approved in Canada; Altimmune Enrolls First Patients in Ph2 ALD Study; MetaVia Doses First Patient in Ph1 Obesity StudyPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jul 09 | 2025Novo Submits High-Dose Sema to EMA; Esperion Generic Bempedoic Acid Settlement; Allurion Files Gastric Balloon to FDA; Arrowhead Initiates Ph3 Zodasiran Study Purchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Jul 02 | 2025Protagonist to Advance Obesity Asset; Syntis Raises $33M Series APurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 30 | 2025Innovent’s Mazdutide Approved in China; Roche Leadership Changes; Apple Tree Partners Legal Battle Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other, Topics Jun 27 | 2025Abvance Receives Financing and Expands Leadership Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 26 | 2025Altimmune MASH Misstep; Novo Partners with WeightWatchers; Novartis Partners for CV Drug Discovery Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 25 | 2025Viking Initiates its Ph3 Study for VK2735; Rivus Shares Topline Ph2 Data in MASH; Lilly Initiates New Ph2 Study of Naperiglipron in Obesity and Ph3 Study of Retatrutide in CLBP; Letter to FDA Pushing for T1DM Treatments; MindRank Announces Ph2b Data for its Oral GLP-1RA Purchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Jun 25 | 2025Thoughts on MariTide Ph2 Data; Amgen ADA 2025 Investor Event Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 23 | 2025ADA 2025 Key Press Releases (June 23) Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 23 | 2025Lilly ADA 2025 Investor Event; Efsitora Alfa QW Insulin Ph3 DataPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Other, Topics Jun 22 | 2025Novo ADA 2025 Investor Event and Full REDEFINE 1 and 2 ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 22 | 2025Beta Bionics Investor Event at ADA 2025Purchase Blast$599
Posted in: Allogeneic, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 22 | 2025ADA 2025 Key Press Releases (June 21) Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Jun 21 | 2025ADA 2025 Key Press Releases (June 20) Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 19 | 2025Zealand Topline Dapiglutide Data; Scholar Rock Ph2 Combination Trial Results; Mineralys Ph2 Topline Data in CKD; Biomea Preclinical Oral GLP-1RA Data Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jun 17 | 2025FDA Commissioner Comments on T1DM at BIO Conference; Lilly Acquires Verve Therapeutics; Metsera Ph1/2 Amylin Trial; Medtronic Invests in India; Allurion Shares Data at ASMBS Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2025Lilly Expands Zepbound SDVs; Ph1 Lilly Amylin Results; D&D Ph2 Obesity Data; MBX Submits IND for Obesity Asset; June CHMP Agenda Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2025Obesity Spotlight: Regeneron’s Obesity Strategy Continues to EvolvePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jun 12 | 2025Novo Advances Amycretin to Ph3; Medtronic Diabetes Reclaims MiniMed Name; Vertex Layoffs After Failed T1DM Program Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jun 11 | 2025Novo Signs Two Obesity Drug Development Partnerships; Lilly Enters Research Collaboration for Muscle Preservation Drug Discovery; Lilly Takes Stance Against Compounders Purchase Blast